EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Histoplasma Antigenuria Prevalence in Patients With Advanced HIV Disease in Côte d’Ivoire: A Prospective Trial Ancillary Study

Aude Sturny-Leclère iD, Ugo Françoise iD, Anani D Badjé iD, Dea Garcia-Hermoso iD, Cyrielle Aka, Hervé Menan iD, Delphine Gabillard iD, Conrad K Muzoora iD, Maryline Bonnet iD, François-Xavier Blanc iD, Olivier Lortholary iD, Alexandre Alanio iD und 3 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf237 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Aude Sturny-Leclère und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycol…. Hauptthemen laut MEDLINE: AIDS-Related Opportunistic Infections, Antigens, Fungal, Histoplasma, Histoplasmosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite tuberculosis being a well-known concern in patients with advanced human immunodeficiency virus (HIV), the STATIS trial, which focused on its management, highlighted significant mortality rates. Histoplasmosis, a fungal disease endemic in sub-Saharan Africa, presents with similar clinical manifestations as tuberculosis. Therefore, it may be prevalent and potentially responsible for deaths in patients with advanced HIV in this region. We conducted an ancillary study of the ANRS STATIS trial to provide the first prevalence estimates of histoplasmosis among individuals with advanced HIV in Côte d'Ivoire.

Methods

We analyzed urine samples from patients previously enrolled in the STATIS trial in Côte d’Ivoire. These ambulatory patients with newly diagnosed HIV infection, CD4+ T-cell counts <100/µL, and eligible for antiretroviral therapy (ART) were randomized to receive either systematic or test-guided tuberculosis treatment. We performed Histoplasma antigen enzyme immunoassay on their urine samples.

Results

The prevalence of Histoplasma antigenuria was 68/280 (24.3%; 95% CI: 19.5%–29.8%), including 52/280 (18.6%; 95% CI: 14.3%–23.7%) symptomatic patients. Of 22 tuberculosis cases documented at inclusion, 8 (36.4%) also had Histoplasma antigenuria. In patients who died within the 48-week follow-up, the prevalence of Histoplasma antigenuria was 15/42 (35.7%% 95% CI: 22.0%–52.0%) compared with 22.3% (95% CI: 17.3%–28.2%) in those surviving. These survivors had a higher body mass index, CD4+ T-cell count, and hemoglobin and platelet count than those who died.

Conclusions

The prevalence of Histoplasma antigenuria was comparable to that of tuberculosis, and histoplasmosis was potentially responsible for preventable deaths. Prospective studies are needed to confirm these findings and promote screening strategies in sub-Saharan Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS-Related Opportunistic InfectionsAntigens, FungalHistoplasmaHistoplasmosisHIV InfectionsAdultFemaleHumansMaleMiddle AgedCD4 Lymphocyte CountCote d'IvoirePrevalenceProspective Studies

Stichwörter der Autor:innen

AfricaHIVantigenhistoplasmosisprevalence

Substanzen

Antigens, Fungal

Autor:innen und Institutionen

  • Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France.
  • Centre d'Investigation Clinique Antilles Guyane INSERM CIC1424, Centre Hospitalier de Cayenne, Cayenne, France.
  • Coordination Régionale de Lutte Contre le VIH COREVIH Guyane, Centre Hospitalier de Cayenne, Cayenne, France.
  • Institut Santé des Populations en Amazonie, Centre Hospitalier de Cayenne, Cayenne, France.
  • Programme ANRS Coopération Côte d'Ivoire (PAC-CI)/ANRS Research Site in Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • INSERM U1219, University of Bordeaux, Institut de Recherche pour le Développement (IRD), Bordeaux, France.

ORCID-Profile: Aude Sturny-Leclère, Ugo Françoise, Anani D Badjé, Dea Garcia-Hermoso, Hervé Menan, Delphine Gabillard, Conrad K Muzoora, Maryline Bonnet, François-Xavier Blanc, Olivier Lortholary, Alexandre Alanio, Antoine A Adenis, Didier Laureillard, Fanny Lanternier

Zitieren

APA

Sturny-Leclère, A., Françoise, U., Badjé, A. D., Garcia-Hermoso, D., Aka, C., Menan, H., Gabillard, D., Muzoora, C. K., Bonnet, M., Blanc, F. X., Lortholary, O., Alanio, A., Adenis, A. A., Laureillard, D., & Lanternier, F. (2025). Histoplasma Antigenuria Prevalence in Patients With Advanced HIV Disease in Côte d’Ivoire: A Prospective Trial Ancillary Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf237

Vancouver

Sturny-Leclère A, Françoise U, Badjé AD, Garcia-Hermoso D, Aka C, Menan H, et al. Histoplasma Antigenuria Prevalence in Patients With Advanced HIV Disease in Côte d’Ivoire: A Prospective Trial Ancillary Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf237

BibTeX
@article{SturnyLeclre2025,
  author = {Sturny-Leclère, Aude and Françoise, Ugo and Badjé, Anani D and Garcia-Hermoso, Dea and Aka, Cyrielle and Menan, Hervé and Gabillard, Delphine and Muzoora, Conrad K and Bonnet, Maryline and Blanc, François-Xavier and Lortholary, Olivier and Alanio, Alexandre and Adenis, Antoine A and Laureillard, Didier and Lanternier, Fanny},
  title = {Histoplasma Antigenuria Prevalence in Patients With Advanced HIV Disease in Côte d’Ivoire: A Prospective Trial Ancillary Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf237}
}
Kostenlos starten →